Method for determining the prognosis of gastric cancer
AssigneeNational Taiwan University
InventorsHsueh-Fen Juan, Chiung-Nien Chen, Chien-Wei Tseng, King-Jen Chang
Life of this patent
Estimating the term…
Abstract
The 14-3-3β protein is used herein as a tumor marker for prognosis in gastric cancer. The method comprises steps of providing a biological sample, qualifying the 14-3-3β protein level in the sample, and comparing the 14-3-3β protein level in the sample with a normal sample. Upon the 14-3-3β protein level in the biological sample is higher than in the normal sample, which represents the patient providing the sample has a poor prognosis. Having the higher sensitivity and specificity, 14-3-3β protein can be used as a tumor marker for prognosis of gastric cancer.
Claims19
A method for determining the prognosis of gastric cancer, comprising:
- providing a biological sample;
- determining an expression level of 14-3-3β protein in the biological sample;
- and
- comparing the expression level of 14-3-3β protein in the biological sample with a reference expression level of 14-3-β protein in a normal sample;
- wherein a poor prognosis is indicated if the expression level of 14-3-3β protein in the biological sample is higher than the reference expression level of 14-3-3β protein of the normal sample.
A method of screening a compound for inhibiting the expression of 14-3-3β protein in a biological sample, comprising:
- contacting a test compound with a biological sample expressing 14-3-3β protein;
- detecting the expression level of 14-3-3β protein in the biological sample;
- and
- selecting the test compound that inhibits the expression level of 14-3-3β protein in the biological sample as compared to the expression level of 14-3-3β protein detected in the absence of the test compound.
A kit comprising an effective dose of an anti-14-3-3β protein antibody for detecting the risk for developing tumor invasion or distal metastatsis of gastric cancer.
Dependencies are inferred from the claim text.